Research Catalog

The acquisition of drug and biologics for chemical and biological warfare defense : Department of Defense interactions with the Food and Drug Administration / Richard A. Rettig, Jennifer Brower, with Orlie Yaniv.

Title
The acquisition of drug and biologics for chemical and biological warfare defense : Department of Defense interactions with the Food and Drug Administration / Richard A. Rettig, Jennifer Brower, with Orlie Yaniv.
Author
Rettig, Richard A.
Publication
Santa Monica, Calif. : Rand, 2003.

Items in the Library & Off-site

Filter by

1 Item

StatusFormatAccessCall NumberItem Location
TextRequest in advance AS36 .R4 MR-1659Off-site

Holdings

Details

Additional Authors
  • Brower, Jennifer, 1967-
  • Yaniv, Orlie.
  • RAND Health
  • National Defense Research Institute (U.S.)
Description
xxi, 76 p.; 24 cm.
Summary
The 1990-1991 Gulf War made clear the U.S. Department of Defense's (DoD's) need to effectively acquire drugs and biologics, mainly vaccines, as American troops faced the real threat of chemical and biological warfare (CBW) agents being used in combat. More than a decade after the war, DoD still experiences acute obstacles in obtaining CBW defense supplies--most recently magnified by the department's attempt to acquire the anthrax vaccine for all its personnel. Key to this acquisition success for the department is its relationship with the U.S. Food and Drug Administration (FDA), which oversees compliance of all licensed drugs and the testing of new medications and vaccines. The DoD-FDA relationship specifically involves matters of licensing, the use of Investigational New Drugs in combat, and the compliance of drug and biologics producers with manufacturing requirements. How can effective communication and procedures improve between the two government entities? The authors recommend such changes as centralizing authority for DoD-FDA relations for CBW drugs and biologics in the Office of the Secretary of Defense and implementing training on FDA regulations for DoD acquisition personnel. Such progress is crucial as the U.S. military faces a variety of new threats in the post-9/11 world.
Subject
  • United States. Department of Defense > Procurement
  • United States. Food and Drug Administration
  • United States. Department of Defense
  • Interinstitutional Relations
  • United States Government Agencies
  • Biological Warfare > prevention & control
  • Chemical Warfare > prevention & control
  • Drug Approval > organization & administration
  • Chemical agents (Munitions) > Safety measures
  • Biological weapons > Safety measures
  • United States
  • United States
  • United States > Medical supplies
Note
  • "MR-1659."
  • "Prepared for the Office of the Secretary of Defense."
Bibliography (note)
  • Includes bibliographical references.
Processing Action (note)
  • committed to retain
ISBN
0833034502 (pbk.)
LCCN
^^2003015371
OCLC
52644347
Owning Institutions
Harvard Library